The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase III randomized trial of neo-adjuvant chemotherapy in high-risk soft tissue sarcoma (ISG-STS 1001): Feasibility and activity of concurrent chemotherapy and radiation therapy.
 
Elena Palassini
Research Funding - Advenchen Laboratories (Inst); Amgen/Dompé (Inst); Arog (Inst); Bayer (Inst); Blueprint Medicines (Inst); Daiichi Sankyo Pharmaceutical (Inst); Deciphera (Inst); Eisai (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Karyopharm Therapeutics (Inst); Lilly O. (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst)
 
Sara Pizzamiglio
No Relationships to Disclose
 
Emanuela Palmerini
Consulting or Advisory Role - Daiichi Sankyo; Deciphera; SynOX
 
Vittorio Quagliuolo
No Relationships to Disclose
 
Javier Martin Broto
Consulting or Advisory Role - Amgen; Asofarma; Bayer; Boehringer Ingelheim; GlaxoSmithKline; Lilly; Novartis; PharmaMar; Roche; Tecnofarma
Speakers' Bureau - PharmaMar
Research Funding - Adaptimmune; Amgen (Inst); Arog (Inst); Ayala Pharmaceuticals (Inst); Bayer (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); CEBIOTEX (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Eisai; Eisai (Inst); FORMA Therapeutics (Inst); GlaxoSmithKline (Inst); Immix BioPharma (Inst); InhibRx (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Lixte Biotechnology (Inst); Nektar (Inst); Novartis; Novartis (Inst); Pfizer (Inst); PharmaMar; PharmaMar (Inst); Philogen (Inst); PTC Therapeutics (Inst); Rain Therapeutics (Inst); SpringWorks Therapeutics (Inst)
Expert Testimony - Novartis; PharmaMar
Travel, Accommodations, Expenses - Pfizer; PharmaMar
 
Giovanni Grignani
No Relationships to Disclose
 
Antonella Brunello
Consulting or Advisory Role - GlaxoSmithKline; PharmaMar
Travel, Accommodations, Expenses - PharmaMar
 
Jean-Yves Blay
Leadership - Innate Pharma
Honoraria - AstraZeneca; Bayer; BMS; Deciphera; Ignyta; MSD; PharmaMar; Roche
Consulting or Advisory Role - Bayer; Blueprint Medicines; Deciphera; Deciphera; Deciphera; Deciphera; Karyopharm Therapeutics; Pharmamar; Roche
Research Funding - AstraZeneca (Inst); Bayer (Inst); BMS (Inst); DEciphera (Inst); GlaxoSmithKline (Inst); MSD (Inst); Novartis (Inst); OSE Pharma (Inst); Pharmamar (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Roche
 
Oscar Tendero
No Relationships to Disclose
 
Robbie Beveridge
No Relationships to Disclose
 
Antonio Lopez Pousa
No Relationships to Disclose
 
Virginia Ferraresi
Consulting or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Novartis
Speakers' Bureau - Bristol-Myers Squibb; MSD Oncology; Novartis; PharmaMar; Pierre Fabre
 
Iwona Lugowska
No Relationships to Disclose
 
Valeria Fontana
No Relationships to Disclose
 
Giuseppe Bianchi
No Relationships to Disclose
 
Silvia Stacchiotti
Honoraria - Aadi; Boehringer Ingelheim; Gentili; GlaxoSmithKline; PharmaMar
Consulting or Advisory Role - Agenus; Astex Pharmaceuticals; Bavarian Nordic; Bayer; Boehringer Ingelheim; Daiichi Sankyo; GlaxoSmithKline; Ikena Oncology; MaxiVax; Novartis; PharmaMar; Rain Therapeutics; Regeneron; SERVIER
Research Funding - Advenchen Laboratories (Inst); Amgen (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Hutchison MediPharma (Inst); InhibRx (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Rain Therapeutics (Inst); SpringWorks Therapeutics (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Angelo Paolo Dei Tos
No Relationships to Disclose
 
Paolo Verderio
No Relationships to Disclose
 
Paolo Giovanni Casali
Research Funding - Advenchen Laboratories (Inst); Amgen/Dompé (Inst); Arog (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Daiihi Sankyo (Inst); Deciphera (Inst); Eisai (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Rain Therapeutics (Inst)
 
Alessandro Gronchi
Honoraria - Deciphera; Lilly; Novartis; Pfizer; PharmaMar
Consulting or Advisory Role - Bayer; Lilly; Nanobiotix; Novartis; Pfizer; PharmaMar; SpringWorks Therapeutics
Research Funding - Nanobiotix (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - Nanobiotix; PharmaMar